Opinion
Video
Ronald D. Alvarez, MD, MBA, gives an analysis of the MIRASOL and DESTINY-PanTumor02 trials, including a comparison of study arms and discussion of HER2/neu targeting.
Lower Odds of Cataract Associated With Antioxidant Index
Five Years Later: Ongoing COVID-19 Challenges, Next Steps
Real-World Data Show Bevacizumab Benefits Only High-Risk Patients With Epithelial Ovarian Cancer
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
Global Analysis Sheds Light on Women’s Cancer Trends
IPF Trial Practices Often Exclude Certain Patients, Perspectives